Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Environmental Science. Processes & Impacts|February 5, 2024
Wildland-urban interface wildfire increases metal contributions to stormwater runoff in Paradise, CaliforniaLauren J Magliozzi, Sandrine J Matiasek, Charles N Alpers, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 4, 2022
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian PopulationXueqing Yu, Nan Chen, Jun Xue, et al.
The New England Journal of Medicine|September 16, 2020
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus NephritisRichard Furie, Brad H Rovin, Frédéric Houssiau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 24, 2021
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus ErythematosusEllen Ginzler, Luiz Sergio Guedes Barbosa, David D'Cruz, et al.
RMD Open|September 17, 2021
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparisonHermine I Brunner, Carlos Abud-Mendoza, Masaaki Mori, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Annals of the Rheumatic Diseases|October 5, 2022
Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reportsMichelle Petri, Helain Landy, Megan E B Clowse, et al.
JCI Insight|December 8, 2022
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndromeXavier Mariette, Francesca Barone, Chiara Baldini, et al.
Rheumatology (Oxford, England)|May 22, 2024
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosusEline J Arends, Mihaela Zlei, Christopher M Tipton, et al.
Pageof 9